| Description | Zandelisib is an inhibitor of phosphatidylinositol 3-kinase (PI3K)(p110δ, IC50 of 3.5 nM), and with antineoplastic activity. |
| In vitro | Zandelisib以IC50分别为4 nM、976 nM、605 nM和3.5 nM抑制PI3Ks（p110α、p110β、p110γ和p110δ）的活性[1]。 |
| Target activity | PI3Kδ:3.5 nM |
| molecular weight | 576.68 |
| Molecular formula | C31H38F2N8O |
| CAS | 1401436-95-0 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 33.33 mg/mL (57.80 mM), when pH Adjusted to 3 with HCl. Sonication and heating to 60℃ are recommended. |
| References | 1. Daniel P. Gold, et al. Combination therapy. WO2019183226A1. 2. David Brown, et al. (sulfinyl and sulfonyl benzimidazolyl) pyrimidines and triazines, pharmaceutical compositions thereof, and their use for treating proliferative diseases. WO2014055647A1. |